SANOFI-AVENTIS (EPA:SAN) New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with CAD, a serious and chronic autoimmune hemolytic anemia

Transparency directive : regulatory news

11/06/2021 09:00


Other stories

14/06/2021 19:42
15/06/2021 03:20
14/06/2021 18:57
15/06/2021 00:07
15/06/2021 00:20
14/06/2021 11:10
14/06/2021 22:55
15/06/2021 02:11
14/06/2021 23:01
14/06/2021 21:21
14/06/2021 23:04
14/06/2021 18:15
14/06/2021 17:47
13/06/2021 19:35
15/06/2021 01:00
14/06/2021 22:29
14/06/2021 22:26
14/06/2021 22:13
14/06/2021 23:41
14/06/2021 17:00
14/06/2021 14:15
14/06/2021 10:13
14/06/2021 23:44
14/06/2021 20:00
14/06/2021 14:47
14/06/2021 17:45
14/06/2021 23:30
14/06/2021 20:00
15/06/2021 01:01
14/06/2021 21:56
15/06/2021 01:44
14/06/2021 12:45
14/06/2021 18:52
14/06/2021 13:49
15/06/2021 01:01
14/06/2021 18:00
14/06/2021 12:40
14/06/2021 17:25